Lindbrook Capital’s Dyne Therapeutics DYN Stock Holding History

Lindbrook Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$6.58K	Buy	629 +410	+187%	+$5.87K	﹤0.01%	1843
2024 Q4	$5.16K	Sell	219 -105	-32%	-$3.11K	﹤0.01%	1973
2024 Q3	$11.6K	Hold	324	–	–	﹤0.01%	1585
2024 Q2	$11.4K	Buy	324 +183	+130%	+$5.32K	﹤0.01%	1555
2024 Q1	$4K	Hold	141	–	–	﹤0.01%	1996
2023 Q4	$1.88K	Buy	141 +5	+4%	+$49	﹤0.01%	2284
2023 Q3	$1.22K	Buy	136 +33	+32%	+$355	﹤0.01%	2296
2023 Q2	$1.16K	Sell	103 -117	-53%	-$1.38K	﹤0.01%	2338
2023 Q1	$2.53K	Buy	220 +117	+114%	+$1.52K	﹤0.01%	2145
2022 Q4	$1.19K	Sell	103 -84	-45%	-$972	﹤0.01%	2421
2022 Q3	$2K	Buy	+187	New	+$2.14K	﹤0.01%	2036
2022 Q2	–	Sell	-437	Closed	-$4K	–	2550
2022 Q1	$4K	Buy	+437	New	+$3.72K	﹤0.01%	1685

Other funds holding DYN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lindbrook Capital's DYN Position: Q1 2025 in Review

Lindbrook Capital increased its Dyne Therapeutics (DYN) stake by 187% in Q1 2025, buying an estimated $5.87K and bringing the position to 629 shares worth $6.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

Lindbrook Capital first reported a position in DYN in Q1 2022 and has held it in 12 quarters since. The position peaked at $11.6K in Q3 2024. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

Lindbrook Capital held 629 shares of Dyne Therapeutics worth $6.58K as of Q1 2025.
Lindbrook Capital bought 410 Dyne Therapeutics shares in Q1 2025, an estimated $5.87K.
Dyne Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1843 holding.
Lindbrook Capital first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 12 quarters since.
Lindbrook Capital's Dyne Therapeutics position peaked at $11.6K in Q3 2024.
205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.